文献速递临床试验与 GCP基础与转化研究

氨甲环酸对肝移植术后早期移植物功能障碍的影响:前瞻性随机对照试验设计

Impact of tranexamic acid on early allograft dysfunction following liver transplantation: study design for a prospective randomized controlled trial.
PubMed 文献 · Trials · 2026-07-07

这是首个探讨预防性氨甲环酸减少肝移植受者EAD的前瞻性随机对照试验。

要点

  • 预防性氨甲环酸组从麻醉诱导至门静脉开放持续输注10 mg/kg/h。
  • 主要目的是验证预防性氨甲环酸能否降低肝移植术后EAD发生率。
  • 这是首个针对该问题的前瞻性随机对照试验,已在中国临床试验注册中心注册。

核心结论

  • 该研究旨在验证肝移植术中预防性使用氨甲环酸可降低早期移植物功能障碍发生率的假设。

研究设计与样本

  • 氨甲环酸组从麻醉诱导至门静脉开放持续输注10 mg/kg/h,安慰剂组输注等体积0.9%氯化钠。
  • 两组麻醉方案相同,均按常规临床实践实施。

关键数值与推荐

  • 氨甲环酸剂量为10 mg/kg/h,从麻醉诱导持续至门静脉开放。
  • 安慰剂为等体积0.9%氯化钠,给药方式相同。

临床怎么用

  • 若试验证实有效,预防性氨甲环酸可能成为减少肝移植术后EAD的围术期策略。

局限性

  • 单中心设计可能限制结果的外推性。
  • 研究方案尚未报告主要终点定义、盲法设置和样本量计算依据等细节。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Hemorrhage and coagulation management are critical during liver transplantation (LT). Hyperfibrinolysis is a major contributor to perioperative blood loss. Tranexamic acid (TA), an antifibrinolytic agent, has been reported to reduce transfusion requirements during LT. Several studies have demonstrated that intraoperative transfusion is independently associated with early graft dysfunction (EAD), which may prolong recovery, increase sepsis incidence, and elevate mortality. However, clinical evidence regarding the prophylactic administration of TA for reducing EAD in LT remains limited. This study aims to test the hypothesis that prophylactic TA use during LT can reduce the incidence of EAD. METHODS: This is a prospective, single-center, randomized, parallel-group study. Two hundred sixty-eight adult participants scheduled for liver transplantation under general anesthesia will be included in this study. In the TA group, participants will receive a continuous infusion of TA (10 mg/kg/h) from anesthesia induction until portal vein unclamping. In the placebo group, an equivalent volume of 0.9% saline will be administered in the same manner. Anesthesia protocol will be identical in both groups and conducted according to routine clinical practice. DISCUSSION: To our knowledge, this is the first prospective randomized controlled trial to investigate whether prophylactic use of TA is effective in reducing EAD incidence for LT recipients. TRIAL REGISTRATION: This trial is registered at www.chictr.org.cn (ChiCTR2300079022). Registered on 23 December 2023. https://www.chictr.org.cn/showproj.html?proj=215007 .

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Zhang Y, Wei X, Liu H, et al. Impact of tranexamic acid on early allograft dysfunction following liver transplantation: study design for a prospective randomized controlled trial. Trials. 2026. PMID: 42410637. doi:10.1186/s13063-026-09678-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。